In vitro and in vivo activity of a palladacycle complex on Leishmania (Leishmania) amazonensis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  de Paladi, Carolina Siqueira ^a   Pimentel, Isabella Aparecida Salerno ^a   Katz, Simone ^a   Cunha, Rodrigo L O R ^b   de Judice, Wagner Alves Souza ^c   Caires, Antonio C F ^c   Barbiéri, Clara Lúcia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^c UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 ETHANEBIS (DIPHENYLPHOSPHINE); AMPHOTERICIN B; CATHEPSIN; CATHEPSIN B; MEGLUMINE ANTIMONATE; PALLADIUM COMPLEX; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; BIPHOSPHINIC PALLADACYCLE COMPLEX; ORGANOMETALLIC COMPOUND;

AMASTIGOTE; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY TEST; FEMALE; HAMSTER; IC 50; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; PARASITE LOAD; PROMASTIGOTE; PROTEIN DEGRADATION; SKIN LEISHMANIASIS; SPECTROFLUOROMETRY; UREA BLOOD LEVEL; ANIMAL; BAGG ALBINO MOUSE; BRAZIL; DISEASE MODEL; DRUG EFFECT; DRUG SENSITIVITY; FLUOROMETRY; HUMAN; ISOLATION AND PURIFICATION; LEISHMANIA MEXICANA; METHODOLOGY; PARASITOLOGY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SYRIAN HAMSTER; TREATMENT OUTCOME;

ANIMALS; ANTIPROTOZOAL AGENTS; BRAZIL; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; FLUOROMETRY; HUMANS; INJECTIONS, SUBCUTANEOUS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MESOCRICETUS; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84863678206     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001626     Document Type: Article

References (48)

1. WHO (2010) Control of leishmaniasis. Report of the Expert Committee. World Health Organization. Tech Rep Ser 949: 1-186.
2. Lainson R, Shaw JJ, (1987) Evolution, classification and geographical distribution. In: Peters W, Killick-Kendrick E, editors. The Leishmaniases in Biology and Medicine London Academic Press pp. 1-120.
3. Goto H, Lindoso JA, (2010) Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419-433.
4. Polonio T, Efferth T, (2008) Leishmaniasis: drug resistance and natural products (review). Int J Mol Med 22: 277-286.
5. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV, (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15: 525-532.
6. Sen R, Chatterjee M, (2011) Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine 18: 1056-1069.
7. Tempone AG, Martins de Oliveira C, Berlinck RG, (2011) Current approaches to discover marine antileishmanial natural products. Planta Med 77: 572-585.
8. Maekawa Y, Himeno K, Ishikawa H, Hisaeda H, Sakai T, et al. (1998) Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol 161: 2120-2127.
9. Ponte-Sucre A, Vicik R, Schultheis M, Schirmeister T, Moll H, (2006) Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob Agents Chemother 50: 2439-2447.
10. Selzer PM, Pingel S, Hsieh I, Ugele B, Chan VJ, et al. (1999) Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc Natl Acad Sci U S A 96: 11015-11022.
11. Desai PV, Patny A, Sabnis Y, Tekwani B, Gut J, et al. (2004) Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J Med Chem 47: 6609-6615.
12. Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, et al. (2006) Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem 49: 1576-1584.
13. Fuertes MA, Nguewa PA, Castilla J, Alonso C, Pérez JM, (2008) Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem 15: 433-439.
14. Caires ACF, (2007) Recent advances involving palladium (II) complexes for the cancer therapy. Anticancer Agents Med Chem 7: 484-491.
15. Higgins JD, Neely L, Fricker S, (1993) Synthesis and cytotoxicity of some cyclometallated palladium complexes. J Inorg Biochem 49: 149-156.
16. Rodrigues EG, Silva LS, Fausto DM, Hayashi MS, Dreher S, et al. (2003) Cyclopalladated compounds as chemotherapeutic agents: antitumor activity against a murine melanoma cell line. Int J Cancer 107: 498-504.
17. Oliveira CR, Barbosa CMV, Nascimento FD, Lanetzki CS, Meneghin MB, et al. (2009) Pre-clinical antitumor evaluation of biphosphinic palladacycle complex in human leukaemia cells. Chem-Biol Interact 177: 181-189.
18. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, et al. (2008) Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 102: 1839-1845.
19. Matsuo AL, Silva LS, Torrecilhas AC, Pascoalino BS, Ramos TC, et al. (2010) In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother 54: 3318-3325.
20. Navarro M, Betancourt A, Hernández C, Marchán E, (2008) Palladium polypyridyl complexes: synthesis, characterization, DNA interaction and biological activity on Leishmania (L.) mexicana. J Braz Chem Soc 19: 1355-1360.
21. Bincoletto C, Tersariol IL, Oliveira CR, Dreher S, Fausto DM, et al. (2005) Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumor agents. Bioorg Med Chem 13: 3047-3055.
22. Barbiéri CL, Doine AI, Freymuller E, (1990) Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp Parasitol 71: 218-228.
23. Zamboni DS, Rabinovitch M, (2003) Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect Immun 71: 1225-1233.
24. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M, (2005) Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 54: 119-122.
25. Lima HC, Bleyenberg JA, Titus RG, (1997) A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 13: 80-82.
26. Robertson CD, Coombs GH, (1990) Characterisation of three groups of cysteine proteases in the amastigotes of Leishmania mexicana mexicana. Mol Biochem Parasitol 42: 269-276.
27. Cotrin SS, Puzer L, Judice WAS, Juliano L, Carmona AK, et al. (2004) Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxypeptidases: assays with human cathepsin B. Anal Biochem 335: 244-252.
28. da Silva EF, Canto-Cavalheiro MM, Braz VR, Cysne-Finkelstein L, Leon LL, et al. (2002) Synthesis, and biological evaluation of new 1,3,4-thiadiazolium-2-phenylamine derivatives against Leishmania amazonensis promastigotes and amastigotes. Eur J Med Chem 37: 979-984.
29. de Souza GF, Yokoyama-Yasunaka JK, Seabra AB, Miguel DC, de Oliveira MG, et al. (2006) Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide 15: 209-216.
30. dos Santos AO, Veiga-Santos P, Ueda-Nakamura T, Filho BP, Sudatti DB, et al. (2010) Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis. Mar Drugs 8: 2733-2743.
31. Guimarães LR, Rodrigues AP, Marinho PS, Muller AH, Guilhon GM, et al. (2010) Activity of the julocrotine, a glutarimide alkaloid from Croton pullei var. glabrior, on Leishmania (L.) amazonensis. Parasitol Res 107: 1075-1081.
32. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR, (2007) Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 60: 526-534.
33. Tanaka AK, Valero VB, Takahashi HK, Straus AH, (2007) Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A. J Antimicrob Chemother 59: 487-492.
34. Croft SL, Craciunescu DG, Certad-Fombona G, (1992) The activity of platinum, iridium, and rhodium drug complexes against Leishmania donovani. Trop Med Parasitol 43: 24-28.
35. Mesa-Valle CM, Rodriguez-Cabezas MN, Moraleda-Lindez V, Craciunescu D, Sanchez-Moreno M, et al. (1998) In vitro and in vivo activity of two Pt(IV) salts against Leishmania donovani. Pharmacology 57: 160-172.
36. Mesa-Valle CM, Moraleda V, Lazuen J, Craciunescu D, Osuna A, (1997) Action of new organometallic complexes against Leishmania donovani. J Antimicrob Chemother 40: 47-57.
37. Etges R, Bouvier J, Bordier C, (1986) The major surface protein of Leishmania promastigotes is a protease. J Biol Chem 261: 9098-9101.
38. Mottram JC, Brooks DR, Coombs GH, (1998) Roles of cysteine proteases of trypanosomes and Leishmania in host-parasite interactions. Cur Opin Microbiol 1: 455-460.
39. Bart G, Frame MJ, Carter R, Coombs GH, Mottram JC, (1997) Cathepsin B-like cysteine protease-deficient mutants of Leishmania mexicana. Mol Biochem Parasitol 88: 53-61.
40. Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ, et al. (1996) Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteases are virulence factors. Proc Natl Acad Sci U S A 93: 6008-6013.
41. Barbosa CM, Oliveira CR, Nascimento FD, Smith MC, Fausto DM, et al. (2006) Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and cell death in K562 leukaemia cells. Eur J Pharmacol 542: 37-47.
42. Santana DP, Faria PA, Paredes-Gamero EJ, Caires ACF, Nantes IL, et al. (2009) Palladacycles catalyse the oxidation of critical thiols of the mitochondrial membrane proteins and lead to mitochondrial permeabilization and cytochrome c release associated with apoptosis. Biochem J 417: 247-256.
43. Bogdan C, Röllinghoff M, (1998) The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28: 121-134.
44. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, et al. (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545-548.
45. Pinheiro RO, Pinto EF, Lopes JR, Guedes HL, Fentanes RF, et al. (2005) TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens. Microbes Infect 7: 1317-1323.
46. Rodrigues V, Silva JS, Campos-Neto A, (1998) Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis. Infect Immun 66: 1233-1236.
47. Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE, (1998) The importance of TGF-beta in murine visceral leishmaniasis. J Immunol 161: 6148-6155.
48. Somanna A, Mundodi V, Gedamu L, (2002) Functional analysis of cathepsin B-like cysteine proteases from Leishamnia donovani complex. Evidence for the activation of latent transforming growth factor beta. J Biol Chem 277: 25305-25312.